These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 14611841)

  • 21. The design and synthesis of aryl hydroxamic acid inhibitors of MMPs and TACE.
    Levin JI
    Curr Top Med Chem; 2004; 4(12):1289-310. PubMed ID: 15320727
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Introduction of the 4-(4-bromophenyl)benzenesulfonyl group to hydrazide analogs of Ilomastat leads to potent gelatinase B (MMP-9) inhibitors with improved selectivity.
    Ledour G; Moroy G; Rouffet M; Bourguet E; Guillaume D; Decarme M; Elmourabit H; Augé F; Alix AJ; Laronze JY; Bellon G; Hornebeck W; Sapi J
    Bioorg Med Chem; 2008 Sep; 16(18):8745-59. PubMed ID: 18782669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and molecular modeling study of iminodiacetyl monohydroxamic acid derivatives as MMP inhibitors.
    Santos MA; Marques SM; Tuccinardi T; Carelli P; Panelli L; Rossello A
    Bioorg Med Chem; 2006 Nov; 14(22):7539-50. PubMed ID: 16875829
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quantitative structure-activity relationship studies on matrix metalloproteinase inhibitors: hydroxamic acid analogs.
    Gupta SP; Kumaran S
    Med Chem; 2006 May; 2(3):243-50. PubMed ID: 16948470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. N-O-isopropyl sulfonamido-based hydroxamates: design, synthesis and biological evaluation of selective matrix metalloproteinase-13 inhibitors as potential therapeutic agents for osteoarthritis.
    Nuti E; Casalini F; Avramova SI; Santamaria S; Cercignani G; Marinelli L; La Pietra V; Novellino E; Orlandini E; Nencetti S; Tuccinardi T; Martinelli A; Lim NH; Visse R; Nagase H; Rossello A
    J Med Chem; 2009 Aug; 52(15):4757-73. PubMed ID: 19606871
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery of gamma-lactam hydroxamic acids as selective inhibitors of tumor necrosis factor alpha converting enzyme: design, synthesis, and structure-activity relationships.
    Duan JJ; Chen L; Wasserman ZR; Lu Z; Liu RQ; Covington MB; Qian M; Hardman KD; Magolda RL; Newton RC; Christ DD; Wexler RR; Decicco CP
    J Med Chem; 2002 Nov; 45(23):4954-7. PubMed ID: 12408705
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First insight into structure-activity relationships of selective meprin β inhibitors.
    Ramsbeck D; Hamann A; Schlenzig D; Schilling S; Buchholz M
    Bioorg Med Chem Lett; 2017 Jun; 27(11):2428-2431. PubMed ID: 28408220
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
    Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y
    J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potent, selective pyrimidinetrione-based inhibitors of MMP-13.
    Reiter LA; Freeman-Cook KD; Jones CS; Martinelli GJ; Antipas AS; Berliner MA; Datta K; Downs JT; Eskra JD; Forman MD; Greer EM; Guzman R; Hardink JR; Janat F; Keene NF; Laird ER; Liras JL; Lopresti-Morrow LL; Mitchell PG; Pandit J; Robertson D; Sperger D; Vaughn-Bowser ML; Waller DM; Yocum SA
    Bioorg Med Chem Lett; 2006 Nov; 16(22):5822-6. PubMed ID: 16942871
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective non-zinc binding MMP-2 inhibitors: Novel benzamide Ilomastat analogs with anti-tumor metastasis.
    Song J; Peng P; Chang J; Liu MM; Yu JM; Zhou L; Sun X
    Bioorg Med Chem Lett; 2016 May; 26(9):2174-8. PubMed ID: 27038494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. NMR-based modification of matrix metalloproteinase inhibitors with improved bioavailability.
    Hajduk PJ; Shuker SB; Nettesheim DG; Craig R; Augeri DJ; Betebenner D; Albert DH; Guo Y; Meadows RP; Xu L; Michaelides M; Davidsen SK; Fesik SW
    J Med Chem; 2002 Dec; 45(26):5628-39. PubMed ID: 12477346
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Alpha,Beta-cyclic-beta-benzamido hydroxamic acids: Novel oxaspiro[4.4]nonane templates for the discovery of potent, selective, orally bioavailable inhibitors of tumor necrosis factor-alpha converting enzyme (TACE).
    Ott GR; Asakawa N; Liu RQ; Covington MB; Qian M; Vaddi K; Newton RC; Trzaskos JM; Christ DD; Galya L; Scholz T; Marshall W; Duan JJ
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1288-92. PubMed ID: 18234496
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Azasugar-based MMP/ADAM inhibitors as antipsoriatic agents.
    Moriyama H; Tsukida T; Inoue Y; Yokota K; Yoshino K; Kondo H; Miura N; Nishimura S
    J Med Chem; 2004 Apr; 47(8):1930-8. PubMed ID: 15055993
    [TBL] [Abstract][Full Text] [Related]  

  • 34. New N-arylsulfonyl-N-alkoxyaminoacetohydroxamic acids as selective inhibitors of gelatinase A (MMP-2).
    Rossello A; Nuti E; Orlandini E; Carelli P; Rapposelli S; Macchia M; Minutolo F; Carbonaro L; Albini A; Benelli R; Cercignani G; Murphy G; Balsamo A
    Bioorg Med Chem; 2004 May; 12(9):2441-50. PubMed ID: 15080939
    [TBL] [Abstract][Full Text] [Related]  

  • 35. X-ray structure of a novel matrix metalloproteinase inhibitor complexed to stromelysin.
    Dunten P; Kammlott U; Crowther R; Levin W; Foley LH; Wang P; Palermo R
    Protein Sci; 2001 May; 10(5):923-6. PubMed ID: 11316871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, preliminary biological evaluation and molecular modeling of some new heterocyclic inhibitors of TACE.
    Sengupta P; Puri CS; Chokshi HA; Sheth CK; Midha AS; Chitturi TR; Thennati R; Murumkar PR; Yadav MR
    Eur J Med Chem; 2011 Nov; 46(11):5549-55. PubMed ID: 21963348
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Design and synthesis of matrix metalloproteinase inhibitors guided by molecular modeling. Picking the S(1) pocket using conformationally constrained inhibitors.
    Hanessian S; MacKay DB; Moitessier N
    J Med Chem; 2001 Sep; 44(19):3074-82. PubMed ID: 11543676
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Beta-aryl-succinic acid hydroxamates as dual inhibitors of matrix metalloproteinases and tumor necrosis factor alpha converting enzyme.
    Kottirsch G; Koch G; Feifel R; Neumann U
    J Med Chem; 2002 May; 45(11):2289-93. PubMed ID: 12014967
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides.
    Tuccinardi T; Martinelli A; Nuti E; Carelli P; Balzano F; Uccello-Barretta G; Murphy G; Rossello A
    Bioorg Med Chem; 2006 Jun; 14(12):4260-76. PubMed ID: 16483784
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sulfonate ester hydroxamic acids as potent and selective inhibitors of TACE enzyme.
    Levin JI; Du MT
    Drug Des Discov; 2003; 18(4):123-6. PubMed ID: 15553924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.